Angiotensin II Receptor Antagonists and Hypertension

References

• Arakawa K. Serine protease angiotensin systems. J Hypertens 1996; 14(suppl 5)3S–7S
   Google Scholar
• Unger T., Chung O., Csikos T., et al. Angiotensin receptors. J Hypertens 1996; 14(suppl 5)S95–S103
   Google Scholar
• Timmermans PBMWM, Wong P. C., Chiu A. T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–251
   PubMed Web of Science ®Google Scholar
• Brunner H. R. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic consideration. Am J Hypertens 1997; 10(12 pt 2)311S–317S
   Google Scholar
• Christen Y., Waeber B., Nussberger J., et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333–1342
   PubMed Web of Science ®Google Scholar
• Müller P., Cohen T., De Gasparo M., et al. Angiotensin II receptor blockade with single doses of valsartan in healthy normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231–45
   PubMed Web of Science ®Google Scholar
• Delacrétaz E., Nussberger J., Biollaz J., Waeber B., Brunner H. R. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14–21
   PubMed Web of Science ®Google Scholar
• Ogihara T., Nagano M., Higaki J., Kohara K., Mikami H. Persistent inhibition of the pressor and aldosterone responses to angiotensin II by TCV-116 in normotensive subjects. J Cardiovasc Pharmacol 1995; 26: 490–494
   PubMed Web of Science ®Google Scholar
• Ribstein J., Picard A., Armagnac C., Sissmann J., Mimran A. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in nonnotensive man. J Cardiovasc Pharmacol, (in press)
   Google Scholar
• Gandhi S. K., Ryder D. H., Brown N. J. Losarian blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 1996; 28: 961–966
   PubMed Web of Science ®Google Scholar
• Cockroft J. R., Sciberras D. G., Goldberg M. R., Ritter J. M. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579–584
   PubMed Web of Science ®Google Scholar
• McIntyre M., Caffe S. E., Michalak R. A., Reid J. L. Losartan an orally active angiotensin receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181–194
   PubMed Web of Science ®Google Scholar
• Markham A., Goa K. L. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299–311
   PubMed Web of Science ®Google Scholar
• Sever P. S. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Human Hypertens 1997; 11(Suppl 2)S91–S95
   Google Scholar
• Reeves R. A., Lin C. S., Kassler-Taub K., Pouleur H. Dose-related efficacy of irbesartan for hypertension. An integrated analysis. Hypertension 1998; 31: 1311–1316
   PubMed Web of Science ®Google Scholar
• McClellan K. J., Balfour J. A. Eprosartan. Drags 1998; 55: 713–718
   Google Scholar
• Gradman A. H., Arcuri K. E., Goldberg K. I., et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345–1350
   PubMed Web of Science ®Google Scholar
• Weber M. A., Byyny R. L., Pratt H., et al. Blood pressure effects of the angiotensin II receptor blocker losartan. Arch Intern Med 1995; 155: 405–411
   PubMed Web of Science ®Google Scholar
• Andersson O. K., Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53–59
   PubMedGoogle Scholar
• Kassler-Taub K., Littlejohn T., Elliott W., Ruddy T., Adler E, Irbesartan/Losartan study investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445–453
   PubMed Web of Science ®Google Scholar
• Soffer B. A., Wright JT, Jr, Pratt J. H., Wiens B., Goldberg Al, Sweet C. S. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–117
   PubMed Web of Science ®Google Scholar
• Laakso M., Karjalainen L., Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392–396
   PubMed Web of Science ®Google Scholar
• Iimura O., Shimamoto K., Matsuda K., et al. Effects of angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor on insulin sensitivity in fructose-fed rats and essential hypertensives. Am J Hypertens 1995; 8: 353–357
   PubMed Web of Science ®Google Scholar
• Israeli Z. H., Hall W. D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Int Med 1992; 117: 234–242
   PubMed Web of Science ®Google Scholar
• Lacourciere Y., Brumnner H., Irwin R., Karlberg B. E., Ramsay B. E., Snavely D. B., Dobbins T. W., Faison E. P., Nelson E. B. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387–1393
   PubMed Web of Science ®Google Scholar
• Sharma P. K., Yium J. J. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90: 552–553
   PubMed Web of Science ®Google Scholar
• Heeringa M. Reversible dysgeusia attributed to losartan. Ann Int Med 1998; 129: 72
   PubMed Web of Science ®Google Scholar
• Mimran A., Ribstein J., Ducailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens 1991; 4: 7–S14S
   Google Scholar
• Toto R. D., Mitchell H. C., Lee H. C., Milam C., Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Int Med 1991; 115: 513–519
   PubMed Web of Science ®Google Scholar
• Demeilliers B., Jover B., Mimran A. Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney one-clip hypertensive rats. J Hypertens 1998; 16: 1023–1029
   PubMed Web of Science ®Google Scholar
• Arzilli F., Favilla S., Motolese M., Peruzzi E., Oddou-Stock P., Salvetti A. Valsartan a new angiotensin II antagonist. Tolerability and effects on renal function in patients with renovascular arterialm hypertension. High Blood Press 1997; 6: 153–158
   Google Scholar
• Mimran A., Ribstein J., DuCailar G. Comparison of the acute renal effect of losartan and captopril in atheromatous renovascular disease. Am J Hypertens 1998; 11A: 47
   Google Scholar
• Holm E. A., Randlov A., Strandgard S. Acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Blood Pressure 1996; 5: 360–362
   PubMedGoogle Scholar
• Missouris C. G., Ward D. E., Eastwood J. B., MacGregor G. A. Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney. Heart 1997; 77: 391–392
   PubMed Web of Science ®Google Scholar
• Ostermann M., Goldsmith DJA, Doyle T., Kingswood J. C., Sharpstone P. Reversible acute renal failure induced by losartan in a renal transplant recipient. Postgrad Med J 1997; 73: 105–107
   PubMed Web of Science ®Google Scholar
• Burnier M., Hagmann M., Nussberger J., Biollaz J., Armagnac C., Brouard R., Waeber B., Brunner H. R. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25(part I)602–609
   PubMedGoogle Scholar
• Price D. A., De Oliveira M., Fisher NDL, Hollenberg N. K. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30(part 1)240–246
   PubMedGoogle Scholar
• Burnier M., Brunner H. R. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nephrol 1996; 4(suppl 1)41–46
   PubMedGoogle Scholar
• Fauvel J. P., Berra N., Pozet N., Madonna P, Zech P., Laville M. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996; 28: 259–263
   PubMed Web of Science ®Google Scholar
• Pechere-Bertschi A., Nussberger J., Decosterd L., Armagnac C., Sissmann J., Bouroudian M., Brunner H. R., Burnier M. Renal response to the angiotensin II receptor subtype I antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998; 16: 385–393
   PubMed Web of Science ®Google Scholar
• Kawabata M., Takabatake T., Ohta H., Nakamura S., Hara H., Ohta K., Takakuwa H., Han W. H., Kobayashi K. I. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Pressure 1994; 3(suppl 5)117–121
   Google Scholar
• Buter H., Navis G., De Zeeuw D., De Jong P. Renal hemodynamic effect of candesartan in normal and impaired renal function in humans. Kidney Int 1997; 52(suppl 63)S185–S187
   Google Scholar
• Gansevoort R. T., De Zeeuw D., De Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system. Kidney Int 1994; 45: 861–867
   PubMed Web of Science ®Google Scholar
• Nielsen S., Dollerup J., Nielsen B., Jensen H. E., Mogensen C. E. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12(suppl 2)19–23
   PubMedGoogle Scholar
• Ilson B. E., Martin D. E., Boike S. C., Jorkasky D. K. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998; 38: 437–441
   PubMed Web of Science ®Google Scholar
• Tsunoda K., Abe K., Hagino T., Omata K., Misawa S., Imai Y., Yoshinaga K. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28–32
   PubMed Web of Science ®Google Scholar
• Sweet C. S., Bradstreet D. C., Berman R. S., Jallard N., Saenz A., Weidler D. J. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035–1040
   PubMed Web of Science ®Google Scholar
• Cuspidi C., Lonati L., Sampieri L., Valagussa L., Macca G., Leonetti G., Zanchetti A. Effects of losartan on blood pressure and left ventricular mass in essential hypertension. High Blood Press 1998; 7: 75–79
   Google Scholar
• Tedesco M. A., Ratti G., Aquino D., Limongelli G., Di Salvo G., Mennella S., Galzerano D., Iarussi D., Iacono A. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Human Hypertens 1998; 12: 505–510
   PubMed Web of Science ®Google Scholar
• Pitt B., Segal R., Martinez F. A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study ELITE). Lancet 1997; 349: 747–752
   PubMed Web of Science ®Google Scholar